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Abstract
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide.
There is currently no effective therapeutic for the treatment of TBI. Primary injury, from
the initial injury, causes contusions and hemorrhaging at the site of impact. Diffuse
damage is caused throughout the brain from the impact; this includes axonal injury,
hypoxic brain damage, brain swelling and vascular injury. Brain damage continues as the
secondary injury; which is characterized by hypoxia, hypotension, amino acid
excitotoxicity and ionic imbalance. All of these conditions cause additional cell death and
damage. Inflammation, brought about by reduced cyclic AMP levels is also seen postinjury. After injury, the glial scar and myelin produce neurite growth inhibitory
molecules. There are several different types of myelin associated inhibitors expressed by
oligodendrocytes; these interact with multiple types of neuron surface receptors
triggering the RhoA cascade, which inhibits actin polymerization and neurite outgrowth.
Chondroitin sulfate proteoglycans (CSPG) expressed on astrocytes also inhibits growth
through the same RhoA pathway. Several strategies have elected to knockdown the RhoA
gene or other genes involved in the growth inhibition pathway.
The objective of this work is to develop novel neuron-specific nanotherapeutics
for combinatorial therapy of drug and small interfering RNA (siRNA) targeting both
extrinsic and intrinsic barriers to neuroplasticity. This neuron-specific polymeric micelle
nanotherapeutics will be designed as follows: First, a cell-type specific targeting moiety
such as an antibody can be conjugated to the polymeric micelle nanoparticle surface to
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deliver nanotherapeutics specifically to neurons. Second, RhoA siRNA, can be targeted
to common intracellular signal transduction pathways for inhibitory molecules such as
myelin and CSPGs. Third, a hydrophobic drug, a phosphodiesterase 4 inhibitor (rolipram)
will be incorporated in the PgP micelle to increase intrinsic neuronal growth capacity by
preventing injury-induced reductions in cAMP levels.
To achieve this goal, we synthesized amphiphilic block copolymers, poly (lactideco-glycolide)- graft-polyethylenimine (PLGA-g-PEI: PgP) using PLGA as a hydrophobic
core forming block and PEI as a hydrophilic shell forming block and characterized the
physico-chemical properties of the PgP micelle as a delivery carrier for combinatorial
therapy of nucleic acid and drug. We demonstrated that the PgP micelle is a promising
nucleic acid delivery carrier using phMGFP plasmid as a reporter gene in C6 (glioma)
cells and primary chick forebrain neurons (CFN) cells in 10% serum containing media in
vitro. We also studied incorporating rolipram in the PgP micelle and successfully
conjugated an antibody (mouse IgG) on the surface of PgP. Currently, we are evaluating
PgP as a siRNA delivery carrier to primary CFN cells and preparing PgP-mNgR1 using
NgR1 monoclonal antibody and evaluating the feasibility of PgP-mNgR1 as a neuronspecific nucleic acid carrier for targeting neuron cells in a rat cortical neuron /astrocyte
co-culture system. In the future, we will study rolipram- loaded PgP-Ab as a nucleic
acid/drug carrier using RhoA siRNA in hypoxic conditions as a TBI model in vitro and a
rat traumatic brain injury model in vivo.
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Chapter 1
Introduction
1.1 Traumatic Brain Injury
Traumatic brain injury (TBI) is caused by a blow to the head which disrupts
normal brain function. It is the most common cause of death and disability in young
people. [1] Each year around 1.7 million traumatic brain injuries occur. The most
common causes of the trauma are falls, vehicle accidents, hitting another object (ex.
children running into wall) and assault. [2] The degree of damage can range from mild to
severe. A mild TBI is usually a concussion with full neurological recovery. Severe TBI is
often characterized by a coma, which has several long term effects. These effects include
loss of cognitive function and motor function, impairment of senses and emotional
changes. The initial trauma, termed as primary injury, from the initial blow causes
localized damages such as brain contusions and hemorrhaging. Diffuse damage also
occurs such as axonal injury, hypoxic brain damage, brain swelling and vascular injury;
however the secondary injury, which happens after the trauma, is the leading cause of in
hospital deaths after TBI. [1,3]
Secondary injury is caused by an increase in intracranial pressure, decrease in
cerebral perfusion and vasogenic fluid accumulation. The secondary injuries lead to
hypoxemia and hypotension, all of which lead to neuronal damage and death. Damage is
also done to the brain chemically. For example, after injury there is an ionic imbalance,
oxidative damage and release of amino acids (ex. glutamine) which cause excitatory
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damage. The damage done to the blood brain barrier allows the influx of cytokines and
chemokines which causes inflammation. [4]
The post-injury remodeling creates an environment that inhibits neuron regrowth
from occurring. The major inhibitory groups are myelin associated inhibitors (MAI) and
chondroitin sulfate proteoglycans (CSPG) associated with the extracellular matrix. Three
common MAIs Nogo, oligodendrocyte- myelin glycoprotein (OMgp) and myelin
associated glycoprotein (MAG) inhibit neurite outgrowth They all bind to the cell surface
Nogo-66 receptor (NgR1) causing activation of the Rho and Rac cascade; inhibiting both
actin polymerization and neurite outgrowth. [5,6] Heavy inflammation is also seen in
TBI, this is caused by injury induced decreases in cyclic AMP (cAMP) levels. cAMP is
involved in the activation of protein kinase A (PKA) which phosphorylates cAMPresponsive element binding protein (CREB). CREB is important for transcription of
survival genes. PKA also phosphorylates nuclear factor-κB which suppresses
inflammatory cytokines. [7]
There have been several different approaches to treating the underlying causes of
traumatic brain injury. One option for increasing cell survival and axon growth is the
delivery of neurotrophins. Studies have used nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5, glial cell-line derived
neurotrophic factor (GDNF) and leukemia inhibitory factor (LIF). Some showed axon
growth and neuron survival. [8] However, neurotrophins also cause additional systemic
effects such as an immune response. [9]
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Neurotrophins stimulate axon growth; however the inhibitory environment caused
by the post-injury remodeling still exists. The glial scar helps create this inhibitory
environment by expressing chondroitin sulfate and keratin. The glial scar may also inhibit
diffusion of growth promoting molecules by creating a physical barrier to diffusion.
CSPGs are upregulated by astrocytes after CNS injury. The effect on growth inhibition
was tested by using a chondroitinase treatment and deletion of scar forming astrocytes.
[10] The study used chondroitinase ABC enzyme (cABC) to digest the CSPG side chains
on the astrocytes. This showed increased axon sprouting after brain injury. [11] Another
group knocked down chondroitin polymerizing factor instead of treating with an enzyme.
The advantage of this method is that CSPGs are continuously synthesized thus an enzyme
treatment may not be sufficient due to short enzyme activity time in vivo. Another
disadvantage of the cABC enzyme is that it may cause an immune response. [10]
The Rho kinase (ROCK) pathway controls CSPG mediated inhibition of growth
but it is also involved with growth inhibition molecules expressed on myelin. [12] These
inhibition molecules, mentioned above are OMpg, MAG and Nogo-A. These factors all
bind strongly to the NgR1 receptor on the surface of neurons. A study which deleted
NgR1 in mice showed less brain injury volume, better performance in motor function
testing, increased neurogenesis and axon sprouting and increased growth associated
protein-43 (GAP-43). [5] GAP-43 is expressed in areas of the brain with higher plasticity
(ex. hippocampus). It is important in the forming of new connections between neurons.
However, MAIs bind to receptors other than NgR1 such as lingo-1 and p75 (TROY).
Another study showed increased functional recovery when deleting the three signaling
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molecules (OMpg, MAG and Nogo-A). [13] However, the CSPG and NgR1 controlled
pathways both involve the Rho kinase so several studies have used this to increase
regrowth. In one study the cells were treated with Y27632 which inhibits ROCK. [12]
The other study researchers knocked down p75, NgR1 and RhoA using siRNA to silence
gene expression. [14]
1.2 Gene Delivery
Gene delivery uses either DNA or RNA to induce or silence production of a
protein. However, in vivo delivery of a nucleic acid without a carrier has many
challenges. This includes degradation by enzymes, serum protein aggregation,
phagocytosis and charge repulsion from the cell membrane; both nucleic acids and cell
membranes are negatively charged. [15] Thus a delivery vehicle is often used being
categorized into viral and non-viral methods.
Viral delivery systems are advantageous because they have high transfection
rates; disadvantages include mutagenesis, carcinogenesis and immune response. The
most popular viruses chosen for gene delivery have been retrovirus and adenovirus.
Retroviruses are made up of double stranded RNA which can also carry foreign DNA.
Long-term gene expression is also seen with cells because the delivered gene integrates
into the host chromosome. Adenoviruses are double stranded DNA viruses which can
also carry foreign DNA. They produce high transfection effic iency with rare chromosome
integration. They have, however received negative attention due to a death caused by
severe immune response. [16]
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Non-viral methods are made up of chemical and physical delivery methods.
Popular chemical methods include cationic lipids and polymers and natural polymers
such as chitosan. Physical delivery methods include gene guns, electroporation and
microinjection. [17] Liposomes are made up of lipids which have a polar head group and
can form either monolayers or bilayers. Lipoplexes are formed when polycationic
liposomes are mixed with polyanionic nucleic acids. Lipoplexes protect the nucleic acid
from degradation. Liposomes have shown good transfection in vitro in non-serum
conditions however when tested in cell cultures with serum and in vivo, they show very
low transfection efficiency. This is because the negative charges on serum proteins
aggregate with liposomes. In the blood stream these large aggregates cannot reach the
target cell because of red blood cell surface absorption or getting trapped in mucus lining
and tight junctions of epithelial cells. [18] PEG-liposomes have also been used to
increase circulation time by shielding the liposome. [19]
Polymer based delivery systems are also used in place of lipids. Cationic
polymers are chosen to form polyplexes with nucleic acids. Branched polyethylenimine,
(PEI 25kDa) is a cationic polymer which has shown high proficiency for endosomal
escape and gene transfer into cells [20]. This property is important because if the
polyplex is contained in the endosome, endosomal enzymes degrade it causing inefficient
gene transfer. PEI has the ability to initiate the proton sponge effect leading to endosomal
escape. At physiological pH the secondary amines on PEI are not protonated;however at
endosomal pH (5.0-5.5) the secondary amines on the PEI become protonated because the
pH is lower than the pKa. [19] The additional positive charges inside the endosome cause
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a charge gradient across the membrane. Negative chlorine ions cross into the endosome
due to this charge gradient. The increase in ions causes increased osmolarity in the
endosome, thus water enters the endosome. The additional water causes the swelling and
bursting of the endosome allowing escape into the cytosol. [18,21] Like lipids PEI has
been PEGylated to reduce interactions with blood components [22]. In addition to PEI
highly branched polymers called dendrimers have also been studies for nucleic acid
delivery. Some examples of dendrimers used are polyamidoamines (PAMAM),
polypropelenimine (PPI). [23]
Polymeric micelles are made up of amphiphilic molecules which self-assemble in
aqueous solution. Micelles are made up of a block copolymer with a hydrophobic (ex.
Poly-lactide) and hydrophilic polymer (ex. Polyethylene glycol). Polymeric micelles are
able to have long circulation times if designed to be larger 42kDa but have a particle size
smaller than 200nm. Being above 42kDa allows micelles to avoid glomular excretion.
Micelles below 200nm avoid recognition by the reticuloendothelial system (RES). This
system works by marking of foreign materials with complement proteins which then
target the material for removal. [19]
1.3 Blood Brain Barrier
The blood brain barrier (BBB) is a major barrier to delivery of therapeutics to the
brain. The composition of the extracellular fluid in the brain is controlled by what can
pass through this barrier. The barrier is made of endothelial cells bound together by tight
junctions. [17] Several options exist to overcome the BBB; lipophilic carriers such as
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liposomes can be used for treatment of the CNS; this is because hydrophilic drugs cannot
pass through the BBB. In addition, a prodrug which is uptaken by the brain can be used.
If a lipophilic option cannot be used the drug can also be conjugated to a peptide which
will cause it to be transported by endocytosis through the endothelial cells which make up
the BBB. [24]
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Chapter 2
Objectives
2.1 Project Objectives
The limitations of current treatment options for traumatic brain injury are that
they only treat a single factor inhibiting neurite regrowth. As described earlier, there are
several factors present in the post-injury remodeling cascade that inhibit regrowth.
Recently, combination therapies, those which treat multiple factors preventing recovery,
for TBI have sparked increasing interest from several national heath institutes. [25]
Because no one treatment option will elicit a total recovery from a severe TBI, the
objective of this project was to develop a combination siRNA and drug therapeutic.
2.2 Therapeutic Carrier Design
The path to this goal started with the synthesis and characterization of a polymeric
micelle to be used in a combination therapy for the treatment of TBI. The polymeric
micelle is to be used as a targeted genetic and drug delivery vehicle. (Fig. 2.1) Anti-NgR1
antibody will be conjugated to the micelle. NgR1 is mostly expressed in neurons, thus the
micelles will be targeted toward neurons so the siRNA and rolipram will only affect
neurons.[26] The gene to be knocked down is RhoA, as stated earlier this is involved in
common pathway shared by several factors which inhibits axon growth. Finally the drug
to be loaded is the phosphodiesterase IV inhibitor rolipram. Rolipram was found to
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restore cAMP levels in vivo. [7,27] Rolipram is a hydrophobic drug thus can be loaded
into the micelle core. [28]

Figure 2.1 Micelle Scheme
Polymeric micelle nanoparticles are made from amphiphilic copolymers. Above a
certain concentration in water, the critical micelle concentration, the polymer forms an
ordered sphere. Due to thermodynamic instability of water interactions with a
hydrophobic polymer the hydrophobic portions aggregate together in the micelle core.
Likewise the hydrophilic portions point outwards. [29] Thus in order to form a micelle
the polymer was designed with a hydrophobic and hydrophilic portion. Poly (Lactide-coglycolide) (PLGA) a biocompatible, biodegradable hydrophobic copolymer was chosen
as the hydrophobic portion of the polymer. [30] The hydrophilic portion of the micelle
will consist of a polycation segment to form a polyplex with nucleic acids. [21] Branched
PEI 25kDa as described above has high proficiency for endosomal escape. PEI also has
the ability to conjugate a targeting antibody. PEI has primary amines which can react
with aldehyde groups on oxidized targeting antibodies to form a Schiff base.[31]Due to
these properties PEI was chosen as, the hydrophilic portion of the polymer. To achieve
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our goal, we synthesized Poly (Lactide-co-Glycolide) –graft-Polyethylenimine (PgP) and
characterized the physical-chemical properties.
2.3 Experimental Design
Three different PgPs were synthesized with branched PEI 25kDa and three
different molecular weights of PLGA (4kDa (lactide:glycolide 50:50), 25kDa
(lactide:glycolide 75:25 ) and 50k (lactide:glycolide 50:50)). A designation was given to
each PgP based on the total PLGA composition. For example, “PgP-12k” is made up of
12kDa of PLGA (3 PLGA 4kDa:1 PEI), “PgP-25k” has 25kDa of PLGA per molecule (1
PLGA 25kDa:1PEI) and “PgP-50k has 50kDa of PLGA per molecule (1 PLGA
50kDA:1PEI). Particle size was used to determine micelle size and pDNA loading ability.
Zeta potential and gel retardation were used to determine pDNA charge neutralization.
N/P ratio is used in place of weight/weight ratio because the positive nitrogen groups on
the polymer are what will bind to the negative phosphate groups on the nucleic acid. [32]
In order to test the ability of PgP to deliver nucleic acids, phMGFP (plasmid
encoding human monster green fluorescent protein pGFP) was used as a reporter gene.
Transfections were performed at various nitrogen/phosphate (N/P) ratios. PEI 5/1 was
used as a positive control because it was previously shown to be the best cationic
polymer for gene delivery. [33] Transfections were done in non-serum conditions and
serum conditions. Serum conditions were used to more closely mimic in vivo conditions.
Non-serum conditions were used as controls to test if PEI neutralization by the negatively
charged serum proteins in serum conditions would cause lower transfection efficiency.
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The hydrophobic drug rolipram was mixed with PgP to determine loading capacity. To
conjugate the antibody to PgP, mouse IgG was oxidized by sodium periodate and then
reacted with the primary amine of PEI in PgP micelles. The effect of antibody
conjugation on transfection efficiency was also tested. To test the effect of Rolipram
loaded PgP on neuronal survival; we used cobalt chloride CoCl2 induced hypoxia as a
model for traumatic brain injury.
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Chapter 3
Materials and Methods
3.1 Materials
Poly (lactic-co-glycolic acid) (PLGA) (4kDa; 50:50, 25kDa; 50:50, and 50 kDa;
75:25) were purchased from Durect Corporation (Cupertino, CA). Anhydrous
dimethylformamide (DMF), N-hydroxysuccidimide (NHS), dicyclocarbodiimide (DCC),
branched polyethylenimine 25kDa (PEI), deuterium oxide (D2 O), sodium periodate,
thiazolyl blue tetrazolium bromide (TBST), 2-mercaptoethanol, methanol, bromophenol
blue, poly-L-lysine (PLL), acetonitrile (ACN), DNaseI and cobalt chloride hexahydrate
were obtained from Sigma-Aldrich (St. Louis, MO). Dialysis tubing (MWCO: 50kDa,
300kDa) were obtained from Spectrum labs (Rancho Dominguez, CA). Unconjugated
mouse IgG was obtained from Rockland Antibodies and Assays (Gilbertsville, PA).
Sodium acetate and paraformaldehyde were purchased from Alfa Asesar (Ward Hill,
MA). Bicinchoninic acid assay (BCA), bovine growth serum (BGS), Fetal bovine serum
(FBS), DMEM/F12 50:50, Dimethyl sulfoxide (DMSO), tris-HCl, tris Base, sodium
dodecyl sulfate (SDS), nitrocellulose membranes, D-glucose, sodium chloride, potassium
chloride, potassium phosphate, sodium phosphate, penicillin, 1% trypsin, 0.25% trypsin
and glycine were obtained from Thermo Fisher Scientific (Waltham, MA).
Polyvinylidene fluoride (PVDF) membranes, Bis-acrylamide, Kaleidoscope ladder,
Ammonium Persulfate and Tetramethylethylenediamine (TEMED) were purchased from
Bio-Rad (Hercules, CA). WesternBreeze with anti-mouse secondary, basal medium eagle

12

(BME), trypsin/EDTA 0.05%, Alexa fluor secondary antibodies and 200mM L-glutamine
were obtained from Life Technologies (Grand Island, NY). C6 cells were obtained from
ATCC (Manassas, VA). Anti-HIF1α was obtained from Millipore (Billerica, MA). AntiβIII tubulin and anti-β-actin antibodies were obtained from Abcam (Cambridge, MA).
Rolipram was purchased from LC Labs (Woburn, MA). The C18 Column was obtained
from Shodex (New York, NY). The Waters 1525 binary HPLC pump, Waters 2998
photodiode array detector, Waters 2414 refractive index detector and Ultrahydrogel 250
column were obtained from Waters (Milford, MA). The 90Plus Particle Size Analyzer
was from Brookhaven Instruments Corporation (Holtsville, NY)
3.2 Synthesis of PgP
3.2.1 Synthesis of PgP
To synthesize PgP-12k, PgP-25k, and PgP-50k, the carboxylic end group on the
PLGA (MW: 4kDa, 25kDa or 50kDa) was activated by NHS and DCC for two hours in
DMF. PgP-12k was synthesized by using a 4:1 mole ratio of PLGA-4kDa to PEI and
PgP-25k and PgP-50k were synthesized by using a 1.2:1mole ratio of PLGA-25kDa and
PgP-50kDa to PEI. After the reaction, the reactant solution was filtered to remove
dicyclohexyl urea. Following filtration, the activated PLGA was reacted with branched
PEI (MW: 25kDa) by adding it drop-wise and then the mixture was allowed to react for
24hrs

at

room

temperature

with

stirring.

Poly

(lactide-co-glycolide)–g-poly

(ethylenimine) (PLGA-g-PEI: PgP) was purified by dialysis against deionized water
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using a membrane filter (MWCO=50,000), filtered with a 0.2µm filter to remove the
precipitate, and then freeze-dried.
Following synthesis and purification, the structure was verified by 1 H- NMR on a
Bruker 300MHz in D2 O. The gel permeation chromatography (GPC) was carried out with
a Waters 1525 binary high performance liquid chromatography (HPLC) pump and
Waters 2414 refractive index detector. The mobile phase was Millipore water at a flow
rate of 0.7mL/min. Injection volume was 20µL and run time was 15 minutes. The
standards used were dextran at molecular weights of 5, 12, 25, 50 and 80kDa.Critical
micelle concentration (CMC) was determined using dye dissolution. 10µL of 0.4mM 1,6
diphenyl- 1,3,5-hexatriene was added to 1mL PgP solutions at various concentrations.
The solutions were incubated in the dark for 6 hrs. Absorbance was taken at 356nm and
used to calculate CMC.
3.2.2 Antibody Conjugation
Antibody conjugation using mouse IgG was accomplished by first oxidizing the
antibody with sodium periodate in isotonic sodium acetate buffer for 2 hours at 4o C. The
reaction was then terminated with ethylene glycol and dialyzed against sodium acetate
once and against isotonic PBS twice to remove excess ethylene glycol and sodium
periodate. [36] Protein concentration was then determined by BCA assay. PgP-12k was
mixed with oxidized antibody to make a 40mg/mL PgP solution with a 50:1 ratio of PgP
to antibody. The solution was mixed overnight at 4 o C and then dialyzed 24 hours against
water (300kDa membrane) to remove unconjugated IgG. Antibody conjugatio n was
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verified by immunoblot assay. A nitrocellulose membrane was washed with tris buffered
saline (TBS) and then dried. Following drying 2µL dots of undialyzed PgP-IgG, dialyzed
PgP-IgG, IgG standards and PgP were spotted on the paper and allowed to dry. Next the
procedure included with the WesternBreeze kit was followed but the primary antibody
step was omitted because the alkaline phosphates secondary antibody (anti-mouse)
recognizes the mouse IgG directly. [37]
3.3 Characterization of PgP/pDNA Polyplexes
3.3.1 Particle Size and Zeta Potential
The particle size and zeta potential of PgP/pDNA polyplexes were determined
by using Brookhaven Instruments Corporation 90Plus Particle Size Analyzer. PgP/pGFP
complexes were prepared at various N/P ratios; PgP was mixed with pGFP (20µg) and
incubated for 30 minutes at 37o C. The solution was transferred to a 2mL cuvette and the
particle size was measured. Particle size was measured three times for two minutes each
using an angle of 90o and wavelength of 659nm. Following particle size measurements,
1.7mL of solution was transferred to a new cuvette and the zeta potential electrode was
inserted into the cuvette. Zeta potential measurements were taken three times.
3.3.2 Gel Retardation
A gel retardation assay was done to determine if DNA was completely
complexed with PgP. 100µL of PgP/pGFP complexes were prepared at various N/P ratios
by mixing PgP with pGFP and incubating for 30 minutes at 37 o C. The agarose gel was
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prepared at 1% with an ethidum bromide concentration of 0.5µg/mL. 10µL of complexes
were mixed with 3µL of loading dye. 10µL of sample was then loaded into each well.
The gel was run at 80V until the xylene cyanol (light blue) dye was 2/3 through the gel.
The images were taken using an Alpha Innotech FlourChem SP imager set to UV
transillumination.
3.4 Cell Culture
C6 rat glioma cells were cultured with DMEM/F12 media supplemented with 5%
BGS and 1% antibiotics at 37o C in 5% CO 2 . Cells were passaged every 2-3 days and
were not kept above passage 10.
Chick forebrain neurons were isolated from day eight embryonic chicks (E8);
chicken eggs obtained from Clemson University Poultry Center and incubated at 37o C
with light rocking. Polystyrene culture plates were coated with PLL by adding 0.01%
PLL solution onto the plates for at least 1 hour and then washing with DI water twice to
remove unbound PLL. After removal of the membrane from the forebrain the brains were
incubated in 0.25% trypsin for 5 minutes at 37o C. The trypsin was then aspirated and the
brains were triturated and suspended in complete media. The neurons were plated at 1
million cells/mL. The neurons were cultured in BME supplemented with 10% FBS,
6mg/mL D-glucose, 2mM L-glutamine and 1% antibiotic at 37o C in 5% CO 2 .
Rat cerebellar neurons were isolated from day 3 postnatal rats. Rat cerebellums
were isolated and the membranes and blood vessels were removed. The cerebellum was
then minced and trypsinized for 15 minutes at 37o C in 1mL of 1% trypsin supplemented
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with 100uL of 1% DNase. The solution was then centrifuged for 3 minutes at 1000 RPM.
Next the trypsin was aspirated and the brains were resuspended in 5mL media and
triturated. The neurons were further homogenized with a 3mL syringe with 22Gx1½
needle. Neurons were cultured on PLL plates as described previously at a concentration
of 1 million cells/mL. [38] The culture medium used was BME supplemented with 10%
FBS, 6 mg/mL D-glucose, 1.5 mg/mL KCl, 2mM L-glutamine and 1% antibiotic at 37o C
in 5% CO 2 .
3.5 Transfection Efficiency and Cytotoxicity
PgP nucleic acid delivery capability was tested using transfection with phMGFP
(pGFP) as a reporter gene. C6 cells were seeded at 1e5 cells/mL in 12 well plates. Plating
media consisted of DMEM/F12 supplemented with 10% FBS and 1% antibiotic. Media
for transfection was either serum containing or serum free depending on conditions
desired. 24 hours after plating PgP/pGFP complexes were prepared at various N/P ratios
on a basis of 2ug of pDNA and 100µL of volume per well. The complexes were well
mixed and incubated for 30 minutes at 37o C. For non-serum conditions, cells were
washed and replaced with serum-free media. After incubation, the complexes were
distributed drop-wise into each well. Four hours after transfection, cells were washed
twice and replaced with 10% serum media. For 10% serum conditions, cells were washed
and replaced with 10% serum media. Complexes were then distributed in the same
manner. 24 hours after transfection, cells were washed twice and replaced with 10%
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serum media. 48 hours after transfection, analysis of cell viability and percent
transfection were performed.
Percent transfection was calculated using flow cytometery on a Millipore
easyCyte flow cytometer with guavaCyte software. The cells were washed with PBS
without calcium and magnesium and trypsinized. The trypsin was neutralized with media
containing serum and the cells were diluted to less than 500 cells/µL. Each sample was
run until 5000 events were counted.
Cell viability testing was calculated using MTT assay; the media was removed
and replaced with serum-free media then 240µL of 2mg/mL TBST solution in PBS with
calcium and magnesium was added to each well drop-wise. The wells were incubated for
4 hours at 37o C, the media was aspirated and the remaining formazan crystals were
dissolved in 1mL DMSO. The absorbance of the solution was read at 570nm.
3.6 Generation of Hypoxia as an in vitro TBI Model
Hypoxia was induced by treating cells with 100µM, 150µM and 200µM CoCl2 in
PBS with calcium and magnesium for 20, 24 and 44 hours. C6 cells were plated at 3e5
cells/mL in 6 well plates. Rat cerebellar neurons were plated at 1 million cells/mL in 6
and 96 well plates. The next day the media was changed and the appropriate amount of
CoCl2 was added to each well. At the desired time points, the cells were lysed using
200uL of RIPA buffer in each well. Total protein was assessed using BCA assay.
Polyacrylamide gels were cast with a 10% resolving gel. Samples were diluted with
reducing sample buffer so that 30µg of total protein was added to each well. After
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dilution the samples were heated for 5 minutes at 60 o C. The gel was run at 100V until
sample buffer reached the bottom of the gel. The proteins were transferred to a PVDF
membrane by western blotting at 30V overnight at 4 o C. Following transfer the membrane
was stained according to the WesternBreeze protocol using chromogenic detection for
both anti-HIFα and anti-β-actin. Immunocytochemistry was done on rat cerebellar
neurons with βIII-tubulin to detect morphological changes.
3.7 Rolipram Loading
Three separate variables were tested for their effect on rolipram loading. Rolipram
amount added to PgP solutions, PgP solution concentration and PgP composition were
tested. PgP-12k, PgP-25k and PgP-50k were used to measure rolipram loading efficiency
with an increase hydrophobic core size. Amount of rolipram was tested by adding 1, 2 or
4mg to PgP to test if supersaturating with drug increased loading amount. Finally,
concentration of PgP solution was tested using 1, 5 or 10mg/mL of PgP solution. The
variables were all tested in parallel; there were three conditions for each of the three
variables yielding 27 different conditions. Rolipram in amounts of 1, 2 or 4mg was
dissolved in PgP 12k, 25k or 50k solutions at concentrations of 1, 5 or 10mg/mL,
respectively. The samples were mixed while shaking for 6 hours at room temperature.
The samples were then filtered with 0.2µm in preparation for HPLC. Reverse phase
HPLC was used to determine rolipram loading. The HPLC was run on a Waters 1525
binary HPLC pump and detected with a Waters 2998 photodiode array detector set to
280nm. The column used was a Shodex C18. The mobile phase was 60:40 Millipore
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water:ACN [28] Rolipram standards were dissolved in DMSO to make a standard curve
of rolipram concentration. Injection volume was 20 µL and run time was 7 minutes. Each
sample made in duplicate and injected twice.
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Chapter 4
Results and Discussion
4.1 Synthesis of PgP
4.1.1 Synthesis of PgP

PgP was synthesized using branched polyethylenimine (b-PEI or PEI, MW 25
kDa) and three different MW of poly-D,L-(lactide-co-glycolide) (PLGA, MW 4 kDa,
25kDa, and 50kDa). Different molecular weights and ratios of lactide:glycolide were
used to change the size of the hydrophobic core used for drug loading. Longer PLGA
molecules were chosen to increase the hydrophobic tail length of the micelle. Higher
lactic acid ratios were chosen to increase hydrophobicity of the polymer tail. Because
there were three different PLGA molecular weights used, three different PgP molecules
were synthesized. Following synthesis and purification, the structure and molecular
weight (MW) of PgP was determined by 1 H NMR and GPC (Fig. 4.1 and 4.2). The
structure of PgP was characterized by 1 H-NMR using D2 O as solvent (δ=2.4~3.5 (m, PEI
backbone -CH2 ), δ=1.4~1.6 (d, 3H, PLGA -CH3 ), δ=4.3 (q, 1H, PLGA-CH), δ=3.9 (s,
2H, PLGA –CH2 )). The degree of PLGA graft to the PEI and molecular weight of PgP
was calculated from the ratio of the integrals of the PEI back bone to methylene of PLGA
(δ=3.9). In case of PgP-12k, approximately three 4 kDa of PLGA are grafted to one PEI
and the molecular weight of PGP was calculated approximately 38,681Da by NMR and
38,168Da by GPC.

In case of PgP-25k, approximately one of 25kDa of PLGA are
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grafted to one PEI and the molecular weight of PgP was calculated approximately
49,275Da by NMR and 48,791Da by GPC (Table 4.1).

Critical micelle concentration (CMC) was calculated creating two linear fits to the
concentration versus absorbance at 356nm. The logarithm of polymer concentration was
plotted against absorbance. The graph shows a rapid spike at the critical micelle
concentration. The intersection of the linear fit from the region before the rapid spike and
after it is used to calculate the critical micelle concentration.
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Figure 4.1 1 H-NMR Spectra of PgP-12k (A), PgP-25k (B), PgP-50k (C)
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D

Figure 4.2 GPC of dextran standards (A), standard curve (B) PgP-12k (C) and
PgP-25k (D)

MW by NMR
PgP-12k
PgP-25k

CMC
MW by GPC
(µM)
38681
38168
18.6
49275
48791
9.3

Table 4.1 NMR, GPC and CMC calculations for PgP at various molecular weights
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4.1.2 Antibody Conjugation to PgP
Antibody conjugation with mouse IgG was verified by immunoblotting (Fig. 4.3).
The density of colorimetric staining was used to compare undialyzed PgP-IgG to dialyzed
PgP-IgG. The undialyzed PgP-IgG showed slightly greater colorimetric staining density
compared to dialyzed PgP-IgG. The difference in colorimetric staining is attributed to
oxidized IgG that was not conjugated to PgP and was thus removed by dialysis. PgP
alone was also immunoblotted to check for background and none was seen.

Figure 4.3 Immunoblot of 300kDa dialyzed PgP-IgG, undialyzed PgP-IgG, PgP and a
serial dilution of IgG alone.
4.2 Characterization of PgP/pDNA Polyplexes
4.2.1 Particle Size and Zeta Potential
The particle size and zeta potentials were measured at various N/P ratios of PgP12k/pGFP. Ratios above 2.5/1 completely neutralized the negative charge of the pDNA
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by complexation with PgP. The particle size was found to be around 200nm. (Fig. 4.4A)
The particle size and zeta potential were also taken for PgP-25k and PgP-50k. At w/w
higher than 1/1 the pDNA was neutralized. The particle sizes were approximately 200nm
and 150nm at all w/w ratios for PgP-25k and PgP-50k respectively. (Fig. 4.4B) The
reason for the lower size with a higher molecular weight is most likely the larger
hydrophobic core forming a tighter micelle. Based on this particle size data PgP-50k may
be the best option for systemic injection in vivo. The reason for this is that particles above
200nm are subject for removal by the reticuloendothelial system [24].

A

BB

Figure 4.4 Particle size and Zeta Potential of PgP-12k, PEI (A), PgP-25k
and PgP-50k (B)

4.2.2 Gel Retardation
Gel retardation was used to determine complex stability. PgP-12k at N/P ratios
above 5/1 showed no pDNA migration, meaning the complex was completely stable.
(Fig. 4.5A). For PgP-12kDa-Ab all w/w ratios used showed complete pDNA complex
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formation (Fig. 4.5B). Weight/weight ratio was used because the exact amount of
conjugated antibody was not known. N/P ratio could not be calculated because of this.

Figure 4.5 Gel retardation of PEI and PgP-12k (A) Lanes: 1 ladder, 2 pGFP, 3 PEI/pGFP
N/P 5/1, 4-9 PgP-12k/pGFP N/P 5/1-30/1. Gel retardation of PEI and PgP-12k-Ab (B)
Lanes: 1 ladder, 2 pGFP, 3 PEI/pGFP N/P 5/1, 4-9 PgP-12k-Ab/pGFP w/w 1/1-6/1

4.3 Transfection Efficiency and Cytotoxicity
First, transfection was done in non-serum conditions because serum severely
inhibits transfection with the positive control PEI. In these conditions, higher ratios of
PgP-12k showed a significant increase in percent transfection compared with PEI with no
significant change in cell viability (Fig. 4.6A, B). Next, transfection was tested in 10%
serum conditions because it more accurately mimics conditions seen in vivo. PEI
performed as expected in serum conditions, with low transfection but PgP-12k showed
increased percent transfection up to an N/P ratio of 30/1 with no decrease in cell viability
(Fig. 4.6A, B). Representative images of C6 cells transfected with PgP-12k/pGFP show
high levels of GFP expression with no change in cell morphology (Fig. 4.7). After
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showing that PgP significantly outperforms PEI in serum conditions, non-serum
conditions were no longer tested. PgP-25k and PgP-50k were tested with higher N/P
ratios due to the higher molecular weights. PgP-25k showed higher transfection with
lower cell viability (Fig. 4.6C, D). The same was true for PgP-50k (Fig. 4.6E, F).
Transfection was also tested using PgP-12k-Ab. The percent transfection was higher than
that of PgP-12k and PEI however the cytotoxicity was higher (Fig. 4.8A, B). All PgP
transfections in C6 cells showed promising transfection results with much higher
transfection than PEI and low to no cytotoxicity. Similar studies have transfected C6 cells
with PEI based nanoparticles in non-serum and serum conditions with varying degrees of
success. One study showed 25% percent transfection with 85% viability in C6 cells. [39]
Another study showed 40% transfection with no cytotoxicity in serum conditions. [42] A
targeting ligand based nanoparticle showed 60% transfection in serum conditions with no
cytotoxicity. [43] Based on these studies our polymer is better than or on par with other
transfections done in the same cell type. This is promising for future studies because we
showed that our polymer has the ability to delivery nucleic acids to cells.
Transfection in CFN was done to show transfection capability in neurons. Nonserum transfection with PgP-12k showed similar percent transfection to PEI 5/1 with
increased cytotoxicity at higher N/P ratios (Fig. 4.9A, B). Serum transfection with PgP12k showed higher transfection than PEI 5/1 however it did show higher cytotoxicity.
PgP-25k showed increased transfection with increasing N/P ratio with high toxicity (Fig.
4.9C, D). PgP-50k showed similar results (Fig. 4.9E, F). While the transfection
percentage was not as high as in C6 cells it is known that non-dividing cells transfect at
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much lower percentages than rapidly dividing ones when using a DNA based reporter.
[41] Other studies have shown low rates of transfection in neurons with lipoplexes,
around 4% hippocampal and cortical neurons. [40] Another showed similar results with
branched PEI transfection in neurons. [44] Our polymer, showed its capability to deliver
pDNA to neurons.
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D
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E

F

A

A

Figure 4.6 C6 cells transfected with PgP-12k/pGFP in 10% serum and non-serum
conditions; percent transfection (A) and cell viability (B). C6 cells transfected with PgP25k/pGFP in 10% serum; percent transfection (C) and cell viability (D). C6 cells
transfected with PgP-25k/pGFP in 10% serum; percent transfection (E) and cell viability
(F). PEI N/P is 5/1 *:P<0.05 for serum conditions, †:P<0.05 for non-serum compared to
PEI
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Figure 4.7 Representative images of transfected C6 cells. Magnification 100x, top: phase
contrast, bottom GFP transfected cells. PEI/pGFP 5/1 (A), PgP-12k/pGFP 5/1, 10/1, 15/1
and 20/1 (B-E respectively)

A

B

Figure 4.8 C6 cells transfected with PgP-12k-Ab/pGFP in 10% serum; percent
transfection (A) and cell viability (B). PEI N/P is 5/1 *:P<0.05 for serum conditions.
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A

Figure 4.9 CFN cells transfected with PgP-12k/pGFP in 10% serum and non-serum
conditions; percent transfection (A) and cell viability (B). CFN cells transfected with
PgP-25k/pGFP in 10% serum; percent transfection (C) and cell viability (D). CFN cells
transfected with PgP-50k/pGFP in 10% serum; percent transfection (E) and cell viability
(F). PEI N/P is 5/1 *:P<0.05 for serum conditions, †:P<0.05 for non-serum compared to
PEI
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4.4 Generation of Hypoxia as an in vitro TBI Model
Western blots done to test for HIF1α in C6 cells showed the highest levels of
protein production with 150µM CoCl2 at 24 and 44 hours. (Fig. 4.10A) Beta actin
blotting showed equal levels of protein levels (Fig. 4.10B), meaning the change in
hypoxia factor was due to hypoxia induction. Neurons were treated with CoCl2 at 100µM
and 150µM for 24 hours to test for hypoxia. After staining with betaIII tubulin noticeably
less neurite outgrowth was seen. (Fig. 4.11)

Figure 4.10 Western blot for HIF1α (A) and beta actin (B) from C6 cells treated with
CoCl2 to induce hypoxia

Figure 4.11 Hypoxia on Rat Cerebellar Neurons stained with BetaIII tubulin. No
treatment (A), 100µM CoCl2 (B), 150µM CoCl2 (C) for 24 each.
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4.5 Rolipram Loading
Rolipram loading was tested by varying rolipram amounts, PgP composition and
PgP concentration. PgP-50k at 10mg/mL using 4mg of rolipram was found to be able to
load the highest amount rolipram. PgP-50k has the longest hydrophobic portion thus
forms a strong hydrophobic core for drug loading (Fig 4.12). Weight of rolipram
dissolved was compared with weight of PgP used (Fig. 4.13, primary axis, colored bars).
It was found that although higher concentrations of PgP were able to load more rolipram
they were not as efficient. This is an important consideration for treatment using rolipram
loaded micelles. In order to use rolipram loaded micelles in vitro the PgP must be diluted
to the concentrations on the order of micrograms. Diluting 10mg/mL PgP to appropriate
concentrations would dilute rolipram more than diluting 1mg/mL PgP to appropriate
concentrations. Higher rolipram amounts added to PgP solutions showed higher loading
amounts. However, higher rolipram amounts were not as efficient as using lower amounts
of rolipram. (Fig. 3.13, secondary axis, white bars)

34

Figure 4.12 PgP loading amounts in PgP-12k, PgP-25k and PgP-50k; each category is
amount of rolipram weighed out. Data points are concentration of rolipram dissolved in
solution calculated from standard curve by HPLC

Figure 4.13 Weight/Weight ratio of rolipram loaded by micelle (µg rolipram)/(mg PgP)
(colored bars); Percent of dry rolipram used loaded by micelle.
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Chapter 5
Conclusion and Future Studies
5.1 Conclusion
The goal of this project was to develop a neuron-specific polymeric
micelle nanoparticle delivery system for combinatorial therapy of an siRNA and a drug.
This study showed that the PgP micelle is an effective nucleic acid delivery vehicle that
can both load drug and conjugate to an antibody. The polymeric micelle was synthesized
successfully and important characteristics were measured. Molecular weight and particle
size were used to characterize the micelle. Particle size, zeta potential and gel retardation
proved stable polyplex formation with pDNA. The critical micelle concentration was
calculated. It was also proven that PgP has the ability to conjugate an antibody. This is
important because the micelle can be conjugated to anti-NgR1 for neuron specific
delivery.
Next, we demonstrated that this PgP micelle is a promising delivery carrier for
nucleic acids and drugs in C6 (glioma) cells and primary CFN cells in 10% serum
containing medium in vitro. The combination of improved transfection and reduced
cytotoxicity in the presence of serum relative to conventional b-PEI (25 kDa) control
suggest PgP may be a promising nucleic acid carrier for in vivo gene delivery. In
addition, transfection using PgP-Ab in C6 cells showed that adding an antibody did not
hinder transfection efficiency or cytotoxicity.
In addition to showing nucleic acid delivery, hydrophobic drug loading capability
of PgP was also demonstrated. The PgP micelle was able to load sufficient amount of
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rolipram for treatment of in vitro cultured neurons. Lastly, an in vitro model for TBI,
hypoxia, was generated using cobalt chloride.
5.2 Limitations and Future Studies
PgP molecular weight was calculated using both 1 H-NMR and GPC; however, the
molecular weight of PgP-50k could not be calculated. We believe this is due to the strong
hydrophobic core formed when the polymer is in aqueous solutions interfering with
measurements. The next steps for characterization of PgP-50k are to determine an
adequate solvent for use in 1 H-NMR and GPC.
Transfection in C6 cells was very successful, with both high transfection
efficiency and low cytotoxicity. Transfection in CFN showed higher cytotoxicity. The
next steps are to use siRNA knockdown to analyze transfection efficacy.
PgP-IgG conjugation was successful. Currently, we are preparing PgP-Ab
(Ab:NgR antibody) and evaluating the feasibility of PgP-Ab as a neuron-specific nucleic
acid (NgR siRNA) carrier for targeting neuron cells in rat cortical neuron/astrocyte coculture system. In the future, we will study rolipram- loaded PgP-Ab as a nucleic
acid/drug carrier using RhoA siRNA in hypoxia conditions in vitro and rat traumatic
brain injury model in vivo.
Rolipram was successfully loaded into the micelle. The next steps are to
determine release of the drug. Using hypoxia as a TBI model, neurons can be treated with
free rolipram, rolipram loaded PgP, no treatment and healthy neurons. The cAMP levels
of cells can then be analyzed using cAMP ELISA to determine release and effectiveness
of rolipram treatments. Finally, an in vivo model of traumatic brain injury will be utilized
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to test the regenerative capacity of our neuron-targeted, rolipram loaded, RhoA siRNA
complexed PgP micelle.
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